Pazopanib 2023 medical insurance price

In 2023, Pazopanib (Pazopanib) original drug has entered the category of Class B medical insurance. There are also domestic drugs produced by other pharmaceutical companies in China, but they are limited to patients with advanced renal cell carcinoma. First-line treatment and patients who have received cytokine therapy for advanced renal cell carcinoma will be reimbursed. Patients who do not meet the conditions can only purchase it at their own expense. The reimbursement ratio is different in different cities, and the price after reimbursement may also be different, but it is relatively cheaper than purchasing it at your own expense.

Pazopanib hydrochloride is an oral multi-target tyrosine kinase receptor inhibitor with anti-tumor activity. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor (PDGFR), and ckit, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Pazopanib hydrochloride is also in Phase II/III development for breast cancer and in Phase II trials in patients with gynecological cancers, non-small cell lung cancer, pancreatic cancer, and glioma. Pazopanib may be superior to currently licensed oral multi-target tyrosine kinase receptor inhibitors in improving efficacy and/or tolerability in patients with metastatic renal cell carcinoma soft tissue sarcoma.

The price of each box of pazopanib original drug on the domestic market may be around RMB 3,000. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.